Last reviewed · How we verify
VPD-737
At a glance
| Generic name | VPD-737 |
|---|---|
| Also known as | Serlopitant |
| Sponsor | Vyne Therapeutics Inc. |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- A Neurokinin-1 Receptor Antagonist for the Treatment of Pruritus in Patients With Epidermolysis Bullosa (PHASE2)
- VPD-737 for Treatment of Chronic Pruritus (PHASE2)
- Study of the Efficacy, Safety and Tolerability of Serlopitant for the Treatment of Pruritus (Itch) With Prurigo Nodularis (PHASE3)
- Study of the Efficacy, Safety, and Tolerability of Serlopitant for the Treatment of Refractory Chronic Cough (PHASE2)
- Study of the Long Term Safety of Serlopitant for the Treatment of Pruritus (Itch) (PHASE3)
- A Randomized Placebo-Controlled Study of the Neurokinin-1 (NK1) Receptor Antagonist Serlopitant Prurigo Nodularis (PN) (PHASE2)
- Study of the Efficacy, Safety, and Tolerability of Serlopitant for the Treatment of Chronic Pruritus of Unknown Origin (PHASE2)
- Study of the Efficacy, Safety and Tolerability of Serlopitant for the Treatment of Pruritus (Itch) With Plaque Psoriasis (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- VPD-737 CI brief — competitive landscape report
- VPD-737 updates RSS · CI watch RSS
- Vyne Therapeutics Inc. portfolio CI